These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29906242)

  • 1. Angiotensin II receptor I blockade prevents stenosis of tissue engineered vascular grafts.
    Ruiz-Rosado JD; Lee YU; Mahler N; Yi T; Robledo-Avila F; Martinez-Saucedo D; Lee AY; Shoji T; Heuer E; Yates AR; Pober JS; Shinoka T; Partida-Sanchez S; Breuer CK
    FASEB J; 2018 Jun; 32(12):fj201800458. PubMed ID: 29906242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGF-β receptor 1 inhibition prevents stenosis of tissue-engineered vascular grafts by reducing host mononuclear phagocyte activation.
    Lee YU; de Dios Ruiz-Rosado J; Mahler N; Best CA; Tara S; Yi T; Shoji T; Sugiura T; Lee AY; Robledo-Avila F; Hibino N; Pober JS; Shinoka T; Partida-Sanchez S; Breuer CK
    FASEB J; 2016 Jul; 30(7):2627-36. PubMed ID: 27059717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts.
    Hibino N; Yi T; Duncan DR; Rathore A; Dean E; Naito Y; Dardik A; Kyriakides T; Madri J; Pober JS; Shinoka T; Breuer CK
    FASEB J; 2011 Dec; 25(12):4253-63. PubMed ID: 21865316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bone Marrow Mononuclear Cell Seeding for Nanofiber Vascular Grafts.
    Fukunishi T; Best CA; Ong CS; Groehl T; Reinhardt J; Yi T; Miyachi H; Zhang H; Shinoka T; Breuer CK; Johnson J; Hibino N
    Tissue Eng Part A; 2018 Jan; 24(1-2):135-144. PubMed ID: 28486019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue Engineering of Vascular Grafts: A Case Report From Bench to Bedside and Back.
    Breuer T; Jimenez M; Humphrey JD; Shinoka T; Breuer CK
    Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):399-409. PubMed ID: 36633008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronate alters natural progression of tissue-engineered vascular grafts.
    Chang YC; Li J; Mirhaidari G; Zbinden J; Barker J; Blum K; Reinhardt J; Best C; Kelly J; Shoji T; Yi T; Breuer C
    FASEB J; 2021 Oct; 35(10):e21849. PubMed ID: 34473380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of human bone marrow mononuclear cell isolation methods for creating tissue-engineered vascular grafts: novel filter system versus traditional density centrifugation method.
    Hibino N; Nalbandian A; Devine L; Martinez RS; McGillicuddy E; Yi T; Karandish S; Ortolano GA; Shin'oka T; Snyder E; Breuer CK
    Tissue Eng Part C Methods; 2011 Oct; 17(10):993-8. PubMed ID: 21609305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deconstructing the Tissue Engineered Vascular Graft: Evaluating Scaffold Pre-Wetting, Conditioned Media Incubation, and Determining the Optimal Mononuclear Cell Source.
    Best C; Tara S; Wiet M; Reinhardt J; Pepper V; Ball M; Yi T; Shinoka T; Breuer C
    ACS Biomater Sci Eng; 2017; 3(9):1972-1979. PubMed ID: 29226239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical study of patient-specific cell-free nanofiber tissue-engineered vascular grafts using 3-dimensional printing in a sheep model.
    Fukunishi T; Best CA; Sugiura T; Opfermann J; Ong CS; Shinoka T; Breuer CK; Krieger A; Johnson J; Hibino N
    J Thorac Cardiovasc Surg; 2017 Apr; 153(4):924-932. PubMed ID: 27938900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a closed system to a standard open technique for preparing tissue-engineered vascular grafts.
    Kurobe H; Maxfield MW; Naito Y; Cleary M; Stacy MR; Solomon D; Rocco KA; Tara S; Lee AY; Sinusas AJ; Snyder EL; Shinoka T; Breuer CK
    Tissue Eng Part C Methods; 2015 Jan; 21(1):88-93. PubMed ID: 24866863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Association of miR-451 with the Incidence of TEVG Stenosis in a Murine Model.
    Hibino N; Best CA; Engle A; Ghimbovschi S; Knoblach S; Nath DS; Ishibashi N; Jonas RA
    Tissue Eng Part A; 2016 Jan; 22(1-2):75-82. PubMed ID: 26573748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-engineered vascular grafts: does cell seeding matter?
    Mirensky TL; Hibino N; Sawh-Martinez RF; Yi T; Villalona G; Shinoka T; Breuer CK
    J Pediatr Surg; 2010 Jun; 45(6):1299-305. PubMed ID: 20620335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantation of inferior vena cava interposition graft in mouse model.
    Lee YU; Yi T; Tara S; Lee AY; Hibino N; Shinoka T; Breuer CK
    J Vis Exp; 2014 Jun; (88):. PubMed ID: 24961688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modeling.
    Best CA; Szafron JM; Rocco KA; Zbinden J; Dean EW; Maxfield MW; Kurobe H; Tara S; Bagi PS; Udelsman BV; Khosravi R; Yi T; Shinoka T; Humphrey JD; Breuer CK
    Acta Biomater; 2019 Aug; 94():183-194. PubMed ID: 31200116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue Engineered Vascular Graft Recipient Interleukin 10 Status Is Critical for Preventing Thrombosis.
    Mirhaidari GJM; Barker JC; Zbinden JC; Santantonio BM; Chang YC; Best CA; Reinhardt JW; Blum KM; Yi T; Breuer CK
    Adv Healthc Mater; 2020 Dec; 9(24):e2001094. PubMed ID: 33073543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of Tissue-Engineered Vascular Grafts.
    Durán-Rey D; Crisóstomo V; Sánchez-Margallo JA; Sánchez-Margallo FM
    Front Bioeng Biotechnol; 2021; 9():771400. PubMed ID: 34805124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue engineered vascular grafts: current state of the field.
    Ong CS; Zhou X; Huang CY; Fukunishi T; Zhang H; Hibino N
    Expert Rev Med Devices; 2017 May; 14(5):383-392. PubMed ID: 28447487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model.
    Fukunishi T; Best CA; Sugiura T; Shoji T; Yi T; Udelsman B; Ohst D; Ong CS; Zhang H; Shinoka T; Breuer CK; Johnson J; Hibino N
    PLoS One; 2016; 11(7):e0158555. PubMed ID: 27467821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time.
    Lee YU; Mahler N; Best CA; Tara S; Sugiura T; Lee AY; Yi T; Hibino N; Shinoka T; Breuer C
    Regen Med; 2016 Mar; 11(2):159-67. PubMed ID: 26925512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again.
    Patterson JT; Gilliland T; Maxfield MW; Church S; Naito Y; Shinoka T; Breuer CK
    Regen Med; 2012 May; 7(3):409-19. PubMed ID: 22594331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.